Real-world Insights into Glimepiride–Metformin Fixed-dose Combinations for Type 2 Diabetes and Hypertension: An Indian Survey
Dr Ram Balak Kumar
, Dr Gautam Kumar , Dr ASHOK KUMAR PANDEY , Dr. Umesh Kumar , Dr. Rajiv Kumar
Type 2 diabetes mellitus; Hypertension; Glimepiride–Metformin fixed-dose combination; Cardiovascular risk; India.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is frequently complicated by hypertension, which significantly increases cardiovascular and renal risk. In India, where the burden of T2DM is high, real-world insights into integrated management strategies remain limited. Glimepiride–Metformin fixed-dose combinations (FDCs) are widely used for glycemic control, yet their role in patients with comorbid hypertension warrants further exploration.
Objective: This study aimed to evaluate clinician perspectives on the use of Glimepiride–Metformin FDCs in T2DM patients with hypertension, focusing on comorbidity patterns, antihypertensive initiation thresholds, adjunctive therapy preferences, titration practices, and perceived therapeutic benefits.
Methods: A cross-sectional survey of 21 healthcare professionals (HCPs) across India was conducted using a structured questionnaire. The responses were analyzed descriptively and contextualized against current guidelines and published evidence.
Results: Hypertension was the most frequently reported comorbidity in T2DM (58%), followed by neuropathy (25%) and coronary artery disease (CAD) (8%). Most HCPs estimated hypertension prevalence in 25%–50% of their patients with T2DM. Antihypertensive therapy was commonly initiated at >140/90 mmHg (33%), with 25% using the tougher >130/80 mmHg threshold. Low-dose diuretics and calcium channel blockers were frequently preferred as adjuncts to RAAS inhibitors. For Glimepiride–Metformin titration, 38% preferred a conservative “start low, go slow” approach, with lower-dose strengths (1–2 mg Glimepiride + 500 mg Metformin) being most prescribed. Clinicians reported benefits beyond glycemic control, including improved blood pressure (BP), lipid profile, weight, and cardiovascular outcomes.
Conclusion: Glimepiride–Metformin FDCs are widely utilized in Indian practice for T2DM with hypertension. Clinicians emphasized their efficacy, safety, cost-effectiveness, and cardiovascular benefits, highlighting their value as part of comprehensive cardiometabolic risk reduction strategies.
"Real-world Insights into Glimepiride–Metformin Fixed-dose Combinations for Type 2 Diabetes and Hypertension: An Indian Survey", IJSDR - International Journal of Scientific Development and Research (www.IJSDR.org), ISSN:2455-2631, Vol.10, Issue 9, page no.a486-a496, September-2025, Available :https://ijsdr.org/papers/IJSDR2509059.pdf
Volume 10
Issue 9,
September-2025
Pages : a486-a496
Paper Reg. ID: IJSDR_304919
Published Paper Id: IJSDR2509059
Downloads: 00083
Research Area: Humanities All
Country: Brahmapura, Muzaffarpur, Bihar, India
ISSN: 2455-2631 | IMPACT FACTOR: 9.15 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 9.15 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJSDR(IJ Publication) Janvi Wave
